Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Koffiekamer  /  Bionano Genomics ($BNGO)

Ontvang nu dagelijks onze kooptips!

word abonnee

Koffiekamer« Terug naar discussie overzicht

Bionano Genomics ($BNGO)

164 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 9 »» | Laatste | Omlaag ↓
  1. [verwijderd] 26 januari 2021 08:39
    workforcenow.adp.com/mascsr/default/m...

    Interessante vacature die via de website van BNGO is te vinden. Zou mogelijk - maar speculatie - kunnen indiceren dat BNGO een eigen CLIA certified laboratorium wil openen / runnen. Wanneer een lab CLIA certification heeft, mag het human tissue in ontvangst nemen voor analyse - wat voor Saphyr uiteraard nodig is.
  5. [verwijderd] 28 januari 2021 09:26
    Een lelijk dagje gisteren, m.i. vooral door de bredere markt en los van de fundamentals van BNGO. Het feit dat Bionano in het Big Ideas rapport van ARK is genoemd is zeer mooi. Het blijf wachten of ze ook nog gaan instappen.
    Fintel.io gaf aan dat het institutional ownership van BNGO met een paar tienden procentpunten is gestegen. Verwacht dat met de binnenstromende 13F-formulieren dat percentage in februari verder op zal lopen. Voorts, met 300 miljoen op de bank, kunnen we mooie catalysts verwachten in de komende periode. Vandaag wellicht ook nog een rood dagje - het hoort er bij.
  6. Morgoth 28 januari 2021 09:57
    Ja, algemene sentiment zal de komende dagen voor nog verdere verkoopdruk zorgen. Heb gisteren alvast op 10,8 terug ingeladen en volgend inlaad-momentje is 9,8 - lange termijn blijft dit bedrijf zeer veel opwaarts potentieel hebben gezien hun unieke technologie. Benieuwd hoe het management hun cash aan het werk gaan zetten om asap hun machientjes aan de man te brengen en grotere omzetten te gaan draaien.
  14. Belegger 86 31 januari 2021 11:58
    quote:

    Bionano Genomics schreef op 29 januari 2021 14:30:

    [...]

    Do your own DD ;)

    Overig nieuws:

    finance.yahoo.com/news/dr-gordana-rac...
    Wederom mooi artikel, aan de werkzaamheid ligt het in ieder geval niet. Ben wel benieuwd hoe ze het in de markt gaan zetten. Als het begin er is en de reacties positief zijn zal het zichzelf op een gegeven moment gaan verkopen.
    Mooi aandeel van een misschien wel toekomstige marktleider om in bezit te hebben.
  15. [verwijderd] 31 januari 2021 12:09
    1) Here is the thread I promised. It is going to a long read so I ask you to bear with me and be patient. I know most of you interested in $BNGO stock do not do genomics and feel intimidated by it so I will try to explain it using an analogy.

    2) First, the Saphyr mapper is not a sequencer, it is, as its name say, a mapper. The difference of a genome sequence and a genome map is that the map aids to decipher the sequence more accurately (for sequence I refer to billions of ATCGATCG…).

    3) A genome map is created before the sequencing begins and provides confidence in the sequence obtained. Therefore, the Saphyr mapper, does not compete or substitute any sequencing technology (either from $PACB, $ILMN, $TMO, etc.), but rather it is —COMPLEMENTARY— to it.

    4) For an analogy, think of an any given address. Imagine I live at 14th Main street, Springfield, Massachusetts, USA. And someone asks me where I live, and I simply answer “Springfield”. If the person is local of Massachusetts, will probably assume that I live in Springfield MA.

    5) However, if I’m asked in a state other than MA, and the person is from a state other than MA, will probably ask “which Springfield”, as there are many cities with this name in all USA; I would have to specify “Springfield, MA.”

    6) If you are familiar with the locality, you will probably assume its broader location. I use this analogy because almost every city in USA has a “Main” street; a lot of states have a “Springfield” city; but also, Main street in Springfield do exists in countries other than USA.

    7) Following this analogy, if we asked, “what is your address?” the most common different sequencing technologies will give, with great precision, the following answers: $ILMN — 14th Main. $TMO — 14th Main. $QGEN — 14th Main. $PACB — 14th Main, Springfield.

    8) None of the above will mention “MA, USA”. Is it possible to locate the accurate address with the first three? NO. Is it possible to locate it with PACB? NOT ENTIRELY.

    9) In the same analogy, if you asked the Saphyr mapper “what is your address?” the answer will be:

    $BNGO — Near Main, Springfield, MA, USA.

    Would you be able to know the precise address? NO. Therefore, there is no technology that could give a complete and accurate answer, yet.

    10) Then why is Bionano’s such a big deal? Because currently, the most common tools for mapping at hospitals and clinics around the world are FISH (fluorescent in situ hybridization), DNA microarrays (commonly known as CMA), chromosome banding (CB), and Karyotypes;

    11) these techniques have existed for at least 20 years and have been the state of the art, so far. What they all have in common is that they are laborious, time consuming and will answer the following to the question “what is your address?”:

    12)

    Karyotype — USA

    Microarays — Springfield

    FISH — MA

    Cromosome banding — Springfield or MA.

    Why is it that people compare Saphyr to PACB? As you can see, the state of the art for the highest precision was held by PACB, but still it won’t give a fully accurate address.

    13) So, if hospitals and clinics around the world needed to figure out what is wrong with your genes at a large scale with the most accurate map/sequence, the only option was PACB.

    14) The biggest disadvantage, however, is that, from all technologies mentioned, PACB is the most expensive and time consuming, and it needs a special expertise that is difficult to find in sequence analysis, hence not many clinics or hospitals even offer this service.

    15) Why is Bionano’s tech the such a big deal? Because it is only as expensive as any of the other mapping tools, it is high throughput, it covers the entire genome(s) at once, it is automated, and it is way more precise than FISH, CMA, CB, and Karyotypes ALL TOGETHER.

    16) Finally, the Saphyr mapper will inexorably find chromosomal re-arrengements missed by PACB—as we all have seen it in their webinars and scientific papers— because they resemble that Springfield was erroneously located in MA, USA—but is rather located in Chelmford, UK.

    17) Why is such a game changer then? Because, if combined, a Saphyr mapper and a sequencing technology (see above) will never miss a mutation or chromosome rearrangement — for large or small this is.

    18) My forecast for the upcoming years is that there will be a massive adoption of mapping tech at hospitals and clinics around the world in the next 5-10 years, which will substitute entirely FISH, CMA, CB, and Karyotypes.

    19) Maybe, if Bionano’s tech is the only one offering optical imaging, it will dominate the entire industry for years.

    As for $BNGO stock price, I have no idea; I am only a scientist that happens to trade.The stock market behaves in ways unpredictable to me.

    20) The only thing I'm certain is that Bionano’s tech is highly disruptive in its niche. And, if there is one thing I've learned from the Market, is that one thing is the company, another thing is its product/service, and a way different beast is its stock price.

    Hope it helps. twitter.com/Fabian_Flores_J/status/13...
  19. Morgoth 3 februari 2021 10:40
    stockinvest.us/stock/BNGO

    Voor deze technische analyse (met een 90% zekerheid/interpreteer het hoe je het zelf wil) zou ik wel willen tekenen als stijging binnen de 3 maanden...

    "...The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 402.15% during the next 3 months and, with a 90% probability hold a price between $24.84 and $67.61 at the end of this 3-month period."
164 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 9 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 858,73 -0,77%
EUR/USD 1,0649 +0,05%
FTSE 100 7.830,29 -0,59%
Germany40^ 17.665,30 -0,96%
Gold spot 2.383,37 +0,17%
NY-Nasdaq Composite 15.601,50 -0,52%

Stijgers

WDP
+3,20%
EBUSCO...
+1,42%
Heineken
+1,32%
Pharming
+1,09%
Vopak
+1,03%

Dalers

VIVORY...
-3,40%
AMG Cr...
-2,78%
Aegon
-2,51%
RENEWI
-2,21%
INPOST
-2,19%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!